Setmelanotide
Also called Imcivree, RM-493
Subcutaneous (under the skin)Product label
Research reference
Product label
Imcivree indication-specific starting schedules
Daily; age ≥12 genetic/BBS group: 2 mg for 2 weeks. Acquired hypothalamic obesity age ≥4: 0.5 mg for 2 weeks
Later increases depend on indication, age, tolerability and kidney function
Imcivree product label ↗When results may show
- When change was measured
- These are different starting groups. Weight/hunger review, skin examination and mood monitoring belong to the clinical plan.
- When to assess
- Later increases depend on indication, age, tolerability and kidney function
- Conditions and limitations
- Specified genetic obesity conditions or acquired hypothalamic obesity; age and kidney function matter. Not a general weight-loss starter. The March 2026 label has distinct age, indication and renal schedules; the adult 2 mg amount must not be generalized.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Sources: Imcivree product label
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Setmelanotide describe 0.5–3 mg per administration. Descriptive only, not a recommendation.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.28× single dose
- Time to steady state
- 2.3days
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Imcivree product labelNot a general weight-loss starter. The March 2026 label has distinct age, indication and renal schedules; the adult 2 mg amount must not be generalized.
Next steps
Setmelanotide beginner guideOpen Setmelanotide planning worksheetEstimate Setmelanotide vial costTrack Setmelanotide notes